NexImmune (NASDAQ:NEXI – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “NexImmune Inc. is a clinical-stage biotechnology company. It engages in developing a novel approach to immunotherapy designed to employ the body’s own […]
NexImmune, Inc. (NASDAQ:NEXI – Get Rating) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 865,000 shares, an increase of 46.6% from the March 15th total of 590,000 shares. Based on an average daily volume of 191,100 shares, the days-to-cover ratio is presently […]
NexImmune (NASDAQ:NEXI – Get Rating) had its target price boosted by Barclays from $4.00 to $7.00 in a report issued on Friday, The Fly reports. They currently have an overweight rating on the stock. Several other equities analysts have also recently weighed in on the stock. Cantor Fitzgerald reiterated an overweight rating on shares of […]
NexImmune, Inc. (NASDAQ:NEXI – Get Rating) Director Grant Verstandig purchased 18,983 shares of NexImmune stock in a transaction that occurred on Monday, March 28th. The shares were bought at an average price of $3.76 per share, for a total transaction of $71,376.08. The transaction was disclosed in a legal filing with the Securities & Exchange […]